Large-scale profiling of metabolic dysregulation in ovarian cancer

International Journal of Cancer

Volumn 136, Issue 3, 2015, Pages 516-526

  Ke, Chaofu ^a   Hou, Yan ^a   Zhang, Haiyu ^a   Fan, Lijun ^a   Ge, Tingting ^a   Guo, Bing ^a   Zhang, Fan ^a   Yang, Kai ^a   Wang, Jingtao ^a   Lou, Ge ^a   Li, Kang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Epithelial ovarian cancer; Metabolic dysregulation; Metabolomics; Plasma

Indexed keywords

ACYLCARNITINE; CA 125 ANTIGEN; CYTOCHROME P450 2E1; DEOXYCHOLIC ACID; HIPPURIC ACID; HISTIDINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOLEPROPIONIC ACID; ISOLEUCINE; KYNURENINE; LACTATE DEHYDROGENASE; PHOSPHOLIPASE A2; PIPERINE; PRASTERONE SULFATE; STEARIC ACID; THYROXINE; TRYPTOPHAN; UNCOUPLING PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BENIGN TUMOR; CANCER LOCALIZATION; CANCER STAGING; CAUSE OF DEATH; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENERGY YIELD; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIPOGENESIS; LIPOLYSIS; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; METABOLIC DISORDER; METABOLOMICS; NATRIURESIS; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PEPTIDE MAPPING; PHOSPHOLIPID METABOLISM; PROTEIN DEGRADATION; PROTEIN METABOLISM; TRYPTOPHAN METABOLISM; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; UTERUS MYOMA; ADOLESCENT; METABOLISM; MIDDLE AGED; NEOPLASM; PATHOLOGY;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; METABOLOMICS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; TRYPTOPHAN;

EID: 84911005369     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29010     Document Type: Article

References (49)

1. Rauh-Hain JA, Krivak TC, Del Carmen MG, et al. Ovarian cancer screening and early detection in the general population. Rev Obstet Gynecol 2011;4:15-21.
2. Ben Sellem D, Elbayed K, Neuville A, et al. Metabolomic characterization of ovarian epithelial carcinomas by HRMAS-NMR spectroscopy. J Oncol 2011;2011:174019.
3. Smith RA, Brooks D, Cokkinides V, et al. Cancer screening in the United States, 2013: a review of current American Cancer Society guidelines, current issues in cancer screening, and new guidance on cervical cancer screening and lung cancer screening. CA Cancer J Clin 2013;63:88-105.
4. Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer Cell 2012;21:297-308.
5. Benjamin DI, Cravatt BF, Nomura DK. Global profiling strategies for mapping dysregulated metabolic pathways in cancer. Cell Metab 2012;16:565-77.
6. Nicholson JK, Lindon JC. Systems biology: metabonomics. Nature 2008;455:1054-6.
7. Zhou M, Guan W, Walker LD, et al. Rapid mass spectrometric metabolic profiling of blood sera detects ovarian cancer with high accuracy. Cancer Epidemiol Biomarkers Prev 2010;19:2262-71.
8. Garcia E, Andrews C, Hua J, et al. Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe. J Proteome Res 2011;10:1765-71.
9. Chen J, Zhang X, Cao R, et al. Serum 27-nor-5beta-cholestane-3,7,12,24,25 pentol glucuronide discovered by metabolomics as potential diagnostic biomarker for epithelium ovarian cancer. J Proteome Res 2011;10:2625-32.
10. Fan L, Zhang W, Yin M, et al. Identification of metabolic biomarkers to diagnose epithelial ovarian cancer using a UPLC/QTOF/MS platform. Acta Oncol 2012;51:473-9.
11. Zhang T, Wu X, Yin M, et al. Discrimination between malignant and benign ovarian tumors by plasma metabolomic profiling using ultra per-formance liquid chromatography/mass spectrometry. Clin Chim Acta 2012;413:861-8.
12. Zhang T, Wu X, Ke C, et al. Identification of potential biomarkers for ovarian cancer by urinary metabolomic profiling. J Proteome Res 2013; 12:505-12.
13. Teneriello MG, Park RC. Early detection of ovarian cancer. CA Cancer J Clin 1995;45:71-87.
14. Smith CA, Want EJ, O'Maille G, et al. XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 2006;78:779-87.
15. Kuhl C, Tautenhahn R, Bottcher C, et al. CAMERA: an integrated strategy for compound spectra extraction and annotation of liquid chromatography/mass spectrometry data sets. Anal Chem 2012;84:283-9.
16. Trygg J, Holmes E, Lundstedt T. Chemometrics in metabonomics. J Proteome Res 2007;6:469-79.
17. Westerhuis JA, Hoefsloot HCJ, Smit S, et al. Assessment of PLSDA cross validation. Metabolomics 2008;4:81-9.
18. Strimmer K. fdrtool: a versatile R package for estimating local and tail area-based false discovery rates. Bioinformatics 2008;24:1461-2.
19. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S1 to analyze and compare ROC curves. BMC Bioinformatics 2011;12:77.
20. Sun M, Gao X, Zhang D, et al. Identification of biomarkers for unstable angina by plasma metabolomic profiling. Mol Biosyst 2013;9:3059-67.
21. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003;13:2498-504.
22. Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009;37:D603-10.
23. Kanehisa M, Goto S, Sato Y, et al. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res 2014;42:D199-205.
24. Odunsi K, Wollman RM, Ambrosone CB, et al. Detection of epithelial ovarian cancer using 1HNMR-based metabonomics. Int J Cancer 2005; 113:782-8.
25. Sutphen R, Xu Y, Wilbanks GD, et al. Lysophospholipids are potential biomarkers of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:1185-91.
26. Fong MY, McDunn J, Kakar SS. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 2011;6:e19963.
27. Ganti S, Taylor SL, Kim K, et al. Urinary acylcarnitines are altered in human kidney cancer. Int J Cancer 2012;130:2791-800.
28. Liu Y. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 2006;9:230-34.
29. Pecqueur C, Bui T, Gelly C, et al. Uncoupling protein-2 controls proliferation by promoting fatty acid oxidation and limiting glycolysis-derived pyruvate utilization. FASEB J 2008;22:9-18.
30. Derdak Z, Mark NM, Beldi G, et al. The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res 2008;68: 2813-9.
31. Nedergaard J, Ricquier D, Kozak LP. Uncoupling proteins: current status and therapeutic prospects. EMBO Rep 2005;6:917-21.
32. Liu F, Bardhan K, Yang D, et al. NF-kappaB directly regulates Fas transcription to modulate Fas-mediated apoptosis and tumor suppression. J Biol Chem 2012;287:25530-40.
33. Sevastou I, Kaffe E, Mouratis MA, et al. Lysoglycerophospholipids in chronic inflammatory disorders: the PLA(2)/LPC and ATX/LPA axes. Biochim Biophys Acta 2013;1831:42-60.
34. Arana L, Gangoiti P, Ouro A, et al. Ceramide and ceramide 1-phosphate in health and disease. Lipids Health Dis 2010;9:15.
35. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
36. Pani G, Galeotti T, Chiarugi P. Metastasis: cancer cell's escape from oxidative stress. Cancer Metastasis Rev 2010;29:351-78.
37. Platten M, Wick W, Van den Eynde BJ. Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion. Cancer Res 2012;72:5435-40.
38. Godin-Ethier J, Hanafi LA, Piccirillo CA, et al. Indoleamine 2,3-dioxygenase expression in human cancers: clinical and immunologic perspectives. Clin Cancer Res 2011;17:6985-91.
39. Soll C, Jang JH, Riener MO, et al. Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 2010;51:1244-54.
40. Rybaczyk LA, Bashaw MJ, Pathak DR, et al. An indicator of cancer: downregulation of monoamine oxidase-A in multiple organs and species. BMC Genomics 2008;9:134.
41. Karbownik M, Reiter RJ, Garcia JJ, et al. Indole-3-propionic acid, a melatonin-related molecule, protects hepatic microsomal membranes from iron-induced oxidative damage: relevance to cancer reduction. J Cell Biochem 2001;81:507-13.
42. Cheng J, Chen C, Kristopher KW, et al. Identification of 2-piperidone as a biomarker of CYP2E1 activity through metabolomic phenotyping. Toxicol Sci 2013;135:37-47.
43. Morita M, Le Marchand L, Kono S, et al. Genetic polymorphisms of CYP2E1 and risk of colorectal cancer: the Fukuoka Colorectal Cancer Study. Cancer Epidemiol Biomarkers Prev 2009;18: 235-41.
44. Li S, Lei Y, Jia Y, et al. Piperine, a piperidine alkaloid from Piper nigrum re-sensitizes P-gp, MRP1 and BCRP dependent multidrug resistant cancer cells. Phytomedicine 2011;19:83-7.
45. Ouyang DY, Zeng LH, Pan H, et al. Piperine inhibits the proliferation of human prostate cancer cells via induction of cell cycle arrest and autophagy. Food Chem Toxicol 2013;60: 424-30.
46. Yang CS, Suh N, Kong ANT. Does vitamin E prevent or promote cancer? Cancer Prev Res 2012;5:701-05.
47. Hori S, Nishiumi S, Kobayashi K, et al. A metabolomic approach to lung cancer. Lung Cancer 2011;74:284-92.
48. Rauschenbach MO, Zharova EI, Sergeeva TI, et al. Blastomogenic activity of phydroxyphenyllactic acid in mice. Cancer Res 1975;35:577-85.
49. http://cancer.stanford.edu/information/cancerDiagnosis/.